Integrated Filing — IndAS



General information about company

Scrip Code 532815
NSE Symbol SMSPHARMA
MSEI Symbol NOTLISTED
ISIN INE812G01025
Name of company SMS PHARMACEUTICALS LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2025
Date of end of financial year 31-03-2026
Date of board meeting when results were approved 22-05-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 16-05-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Fourth quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Audited
Segment Reporting Single segment
Description of single segment Manufacture of Active Pharmaceutical Ingredients(Bulk Drugs), Peptides and Intermediates
Start date and time of board meeting 22-05-2026   10:30:00
End date and time of board meeting 22-05-2026   13:35:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 08-11-2024
Indicate Company website link for updated RPT policy of the Company https://smspharma.com/corporate-governance/governance-documents-policies/
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? Yes
No. of times funds raised during the quarter 1
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
Not Applicable as there is no default.



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-01-2026 01-04-2025
B Date of end of reporting period 31-03-2026 31-03-2026
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
1 Income
Revenue from operations 23,794.75 88,687.10
Other income 257.44 835.38
Total income 24,052.19 89,522.48
2 Expenses
(a) Cost of materials consumed 12,831.07 51,687.27
(b) Purchases of stock-in-trade 0.00 0.00
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade 500.89 (2,284.17)
(d) Employee benefit expense 2,943.49 8,792.34
(e) Finance costs 527.67 2,307.56
(f) Depreciation, depletion and amortisation expense 1,013.09 3,991.93
(f) Other Expenses
1 Manufacturing Expenses 2,344.83 9,070.22
2 Other Expenses 1,186.59 4,330.20
Total other expenses 3,531.42 13,400.42
Total expenses 21,347.63 77,895.35
3 Total profit before exceptional items and tax 2,704.56 11,627.13
4 Exceptional items 0.00 0.00
5 Total profit before tax 2,704.56 11,627.13
6 Tax expense
7 Current tax 543.31 2,593.31
8 Deferred tax 69.16 272.89
9 Total tax expenses 612.47 2,866.20
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 2,092.09 8,760.93
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period 2,092.09 8,760.93
17 Other comprehensive income net of taxes 23.44 3.31
18 Total Comprehensive Income for the period 2,115.53 8,764.24
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 936.52 936.52
Face value of equity share capital 1 1
27 Details of debt securities
22 Reserves excluding revaluation reserve 79,542.17
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 2.29 9.58
Diluted earnings (loss) per share from continuing operations 2.29 9.58
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 2.29 9.58
Diluted earnings (loss) per share from continuing and discontinued operations 2.29 9.58
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2025
Date of end of reporting period 31-03-2026
Whether results are audited or unaudited Audited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 53,121.67
Capital work-in-progress 11,582.43
Investment property 0.00
Goodwill 0.00
Other intangible assets 279.60
Intangible assets under development 0.00
Biological assets other than bearer plants 0.00
Investments accounted for using equity method 0.00
Non-current financial assets
Non-current investments 5,210.60
Trade receivables, non-current 0.00
Loans, non-current 0.00
Other non-current financial assets
1 Bank Balances 396.32
2 Other non-current financial assets 723.38
Total of other non-current financial assets 1,119.70
Total non-current financial assets 6,330.30
Deferred tax assets (net)
Other non-current assets
1 Other non-current assets 3,129.25
Total of other non-current assets 3,129.25
Total non-current assets 74,443.25
2 Current assets
Inventories 35,095.32
Current financial asset
Current investments 0.00
Trade receivables, current 21,587.70
Cash and cash equivalents 4,578.15
Bank balance other than cash and cash equivalents 19.78
Loans, current 0.00
Other current financial assets
Total of other current financial assets 344.81
Total current financial assets 26,530.44
Current tax assets (net) 0.00
Other current assets
1 Other current assets 2,031.03
Total of other current assets 2,031.03
Total current assets 63,656.79
3 Non-current assets classified as held for sale 0.00
4 Regulatory deferral account debit balances and related deferred tax Assets 0.00
Total assets 1,38,100.04
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 936.52
Other equity 79,542.17
Total equity attributable to owners of parent 80,478.69
Non controlling interest
Total equity 80,478.69
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 17,164.01
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0.00
Total Trade payable 0.00
Other non-current financial liabilities
Total of other non-current financial liabilities
Total non-current financial liabilities 17,164.01
Provisions, non-current 119.86
Deferred tax liabilities (net) 5,083.76
Deferred government grants, Non-current 0.00
Other non-current liabilities
Total of other non-current liabilities
Total non-current liabilities 22,367.63
Current liabilities
Current financial liabilities
Borrowings, current 19,340.79
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 24.67
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 12,014.51
Total Trade payable 12,039.18
Other current financial liabilities
1 Other financial liabilities 3,136.93
Total of other current financial liabilities 3,136.93
Total current financial liabilities 34,516.90
Other current liabilities 582.87
1 Other current liabilities 582.87
Total of other current liabilities 582.87
Provisions, current 92.46
Current tax liabilities (Net) 61.49
Deferred government grants, Current 0.00
Total current liabilities 35,253.72
3 Liabilities directly associated with assets in disposal group classified as held for sale 0.00
4 Regulatory deferral account credit balances and related deferred tax liability 0.00
Total liabilities 57,621.35
Total equity and liabilites 1,38,100.04
Disclosure of notes on assets and liabilities



Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-01-2026 01-04-2025
Date of end of reporting period 31-03-2026 31-03-2026
Whether results are audited or unaudited Audited Audited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-01-2026 01-04-2025
B Date of end of reporting period 31-03-2026 31-03-2026
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
Total Amount of items that will not be reclassified to profit and loss
2 Income tax relating to items that will not be reclassified to profit or loss (23.44) (3.31)
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss 0.00 0.00
5 Total Other comprehensive income 23.44 3.31



Cash flow statement, indirect

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2025
B Date of end of reporting period 31-03-2026
C Whether results are audited or unaudited Audited
D Nature of report standalone or consolidated Standalone
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 11,627.13
Adjustments for reconcile profit (loss)
Adjustments for finance costs 2,184.36
Adjustments for decrease (increase) in inventories (6,622.41)
Adjustments for decrease (increase) in trade receivables, current (1,264.34)
Adjustments for decrease (increase) in trade receivables, non-current 0.00
Adjustments for decrease (increase) in other current assets (650.21)
Adjustments for decrease (increase) in other non-current assets (2,230.02)
Adjustments for other financial assets, non-current (28.60)
Adjustments for other financial assets, current 626.32
Adjustments for other bank balances 0.00
Adjustments for increase (decrease) in trade payables, current 647.99
Adjustments for increase (decrease) in trade payables, non-current 0.00
Adjustments for increase (decrease) in other current liabilities 124.37
Adjustments for increase (decrease) in other non-current liabilities 0.00
Adjustments for depreciation and amortisation expense 3,991.93
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0.00
Adjustments for provisions, current 0.00
Adjustments for provisions, non-current 0.00
Adjustments for other financial liabilities, current 126.11
Adjustments for other financial liabilities, non-current 0.00
Adjustments for unrealised foreign exchange losses gains 0.00
Adjustments for dividend income 0.00
Adjustments for interest income 61.86
Adjustments for share-based payments 0.00
Adjustments for fair value losses (gains) 0.00
Adjustments for undistributed profits of associates 0.00
Other adjustments for which cash effects are investing or financing cash flow 0.00
Other adjustments to reconcile profit (loss) 0.00
Other adjustments for non-cash items 7.37
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments for reconcile profit (loss) (3,148.99)
Net cash flows from (used in) operations 8,478.14
Dividends received 0.00
Interest paid 0.00
Interest received 0.00
Income taxes paid (refund) 2,410.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) operating activities 6,068.14
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0.00
Cash flows used in obtaining control of subsidiaries or other businesses 0.00
Other cash receipts from sales of equity or debt instruments of other entities 0.00
Other cash payments to acquire equity or debt instruments of other entities 0.00
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0.00
Proceeds from sales of property, plant and equipment 0.00
Purchase of property, plant and equipment 12,510.50
Proceeds from sales of investment property 0.00
Purchase of investment property 0.00
Proceeds from sales of intangible assets 0.00
Purchase of intangible assets 0.00
Proceeds from sales of intangible assets under development 0.00
Purchase of intangible assets under development 0.00
Proceeds from sales of goodwill 0.00
Purchase of goodwill 0.00
Proceeds from biological assets other than bearer plants 0.00
Purchase of biological assets other than bearer plants 0.00
Proceeds from government grants 0.00
Proceeds from sales of other long-term assets 0.00
Purchase of other long-term assets 0.00
Cash advances and loans made to other parties 0.00
Cash receipts from repayment of advances and loans made to other parties 0.00
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 0.00
Interest received 79.99
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash (802.20)
Net cash flows from (used in) investing activities (13,232.71)
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0.00
Payments from changes in ownership interests in subsidiaries 0.00
Proceeds from issuing shares 0.00
Proceeds from issuing other equity instruments 4,762.07
Payments to acquire or redeem entity's shares 0.00
Payments of other equity instruments 0.00
Proceeds from exercise of stock options 0.00
Proceeds from issuing debentures notes bonds etc 0.00
Proceeds from borrowings 8,842.36
Repayments of borrowings 3,435.20
Payments of lease liabilities 0.00
Dividends paid 354.61
Interest paid 2,211.17
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) financing activities 7,603.45
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes 438.88
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0.00
Net increase (decrease) in cash and cash equivalents 438.88
Cash and cash equivalents cash flow statement at beginning of period 4,139.27
Cash and cash equivalents cash flow statement at end of period 4,578.15





Details of Impact of Audit Qualification

Amount in (Lakhs)

Whether results are audited or unaudited Audited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 M/s.Suryanarayana & Suresh, Chartered Accountants Yes 31-07-2026


Statement on Deviation or Variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement Etc. (1)

Amount in (Lakhs)

Mode of Fund Raising Preferential Issues
Description of mode of fund raising (Applicable in case of others is selected)
Date of Raising Funds 19-03-2024
Amount Raised 11,430.00
Report filed for Quarter ended 31-03-2026
Monitoring Agency Applicable
Monitoring Agency Name, if applicable CARE Ratings Limited
Is there a Deviation / Variation in use of funds raised No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders
If Yes, Date of shareholder Approval
Explanation for the Deviation / Variation NIL
Comments of the Audit Committee after review NIL
Comments of the auditors, if any NIL
Sr. Original Object Modified Object, if any Original Allocation Modified allocation, if any Funds Utilised Amount of Deviation/Variation for the quarter according to applicable object Remarks if any
1 Capital Expenditure: Expansion of production capacities in phased manner and installation of additional utility equipments as well as recovery systems. Proposed to start backward integration of Key Starting Materials (KSM) for existing as well as new products under pipeline at R&D by setting up new production blocks. NA 6,287.00 0.00 6,340.00 0.00 The Company has fully utilized the issue proceeds amounting to Rs.114.30 Crores towards the objects of the issue by the quarter ended 31st March, 2026. Accordingly , this is the final Statement of Deviation and Variation.
2 Working Capital: Expanding the production capacities, backward integration of KSM, which led to an increased requirement of Working Capital, operational expenditure and other related expenses. NA 4,000.00 0.00 4,000.00 0.00
3 General Corporate Purposes: which includes, inter alia, meeting ongoing general corporate exigencies and contingencies, expenses of the Company as applicable in such a manner and proportion as may be decided by the Board from time to time, and/or any other general purposes as may be permissible under applicable laws. NA 1,143.00 0.00 1,089.00 0.00


Signatory Details

Name of signatory Lakshmi Narayana Tammineedi
Designation of person Chief Financial Officer
Place Hyderabad
Date 22-05-2026




Amount in (Lakhs)

Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)

Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity/subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of the related party transaction ratified by the audit committee Date of Audit Committee Meeting where the ratification was approved Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 SMS Pharmaceuticals Limited VKT Pharma Private Limited Associate Company Sale of goods or services 17,000.00 NIL 3,185.79 2,215.62 3,069.80
2 SMS Pharmaceuticals Limited VKT Pharma Private Limited Associate Company Purchase of goods or services 300.00 NIL 0.00 0.00 0.00
3 SMS Pharmaceuticals Limited VKT Pharma Private Limited Associate Company Any other transaction other reimbusement 100.00 NIL 0.00 0.00 0.00
4 SMS Pharmaceuticals Limited VKT Pharma Private Limited Associate Company Any other transaction Rent Received 100.00 NIL 14.53 2.22 2.22
5 SMS Pharmaceuticals Limited Haleos Labs Ltd (Formerly know as SMS Lifesciences India Limited) Promoters holding more than 10 % of total equity Purchase of goods or services 2,500.00 NIL 498.33 (888.40) (316.80)
6 SMS Pharmaceuticals Limited Haleos Labs Ltd (Formerly know as SMS Lifesciences India Limited) Promoters holding more than 10 % of total equity Sale of goods or services 500.00 NIL 0.00 0.00 0.00
7 SMS Pharmaceuticals Limited Raghavendra Engineering Industries Private Limited Relative of Promoter Purchase of goods or services 3,000.00 NIL 1,291.64 19.21 18.28
8 SMS Pharmaceuticals Limited Raghavendra Engineering Industries Private Limited Relative of Promoter Sale of goods or services 150.00 NIL 0.00 0.00 0.00
9 SMS Pharmaceuticals Limited Four's' Engineering Works Relative of Promoter Purchase of goods or services 500.00 NIL 64.46 (42.16) (80.18)
10 SMS Pharmaceuticals Limited Eshwar Coal Movers Relative of Promoter Purchase of goods or services 500.00 NIL 218.21 (26.13) (92.49)
11 SMS Pharmaceuticals Limited SMS Peptides Private Limited Subsidiary Company Purchase of goods or services 500.00 NIL 0.00 0.00 0.00
12 SMS Pharmaceuticals Limited SMS Peptides Private Limited Subsidiary Company Sale of goods or services 500.00 NIL 0.00 0.00 0.00
13 SMS Pharmaceuticals Limited SMS Peptides Private Limited Subsidiary Company Any other transaction Rent Received 100.00 NIL 7.08 0.00 1.08
14 SMS Pharmaceuticals Limited SMS Peptides Private Limited Subsidiary Company Any other transaction Investment 1,000.00 NIL 399.00 0.00 0.00
15 SMS Pharmaceuticals Limited Ramesh Babu Potluri Key Managerial Personnel Remuneration NIL 492.52 (140.63) (211.37)
16 SMS Pharmaceuticals Limited Vamsi Krishna potluri Key Managerial Personnel Remuneration NIL 579.07 (281.18) (295.28)
17 SMS Pharmaceuticals Limited Lakshmi Narayana Tammineedi Key Managerial Personnel Remuneration NIL 20.86 (2.57) (2.37)
18 SMS Pharmaceuticals Limited Thirumalesh Tumma Key Managerial Personnel Remuneration NIL 8.97 (1.27) (1.27)
19 SMS Pharmaceuticals Limited Shravan Kudaravalli Director Any other transaction Sitting fee NIL 5.00 0.00 0.00
20 SMS Pharmaceuticals Limited Sarvepalli Srinivas Director Any other transaction Sitting fee NIL 3.50 0.00 0.00
21 SMS Pharmaceuticals Limited Trilok Potluri Director Any other transaction Sitting fee NIL 3.00 0.00 0.00
22 SMS Pharmaceuticals Limited Sunkara Venkata Satya Shiva Prasad Director Any other transaction Sitting fee NIL 1.50 0.00 0.00
23 SMS Pharmaceuticals Limited Suresh Kumar Gangavarapu Director Any other transaction Sitting fee NIL 4.00 0.00 0.00
24 SMS Pharmaceuticals Limited Shanti Sree Bolleni Director Any other transaction Sitting fee NIL 5.00 0.00 0.00
Total value of transaction during the reporting period 6,802.46